(Q45006426)

8 December 2017

title

Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. (English)

1 reference

8 December 2017

Jeffs SA

1

1 reference

8 December 2017

Goriup S

2

1 reference

8 December 2017

Kebble B

3

1 reference

8 December 2017

Crane D

4

1 reference

8 December 2017

Bolgiano B

5

1 reference

8 December 2017

Sattentau Q

6

1 reference

8 December 2017

Jones S

7

1 reference

8 December 2017

Holmes H

8

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

8 December 2017

1 reference

8 December 2017

volume

22

1 reference

8 December 2017

issue

8

1 reference

8 December 2017

page(s)

1032-1046

1 reference

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

8 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

A vaccine for HIV type 1: the antibody perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Why do we not have an HIV vaccine and how can we make one? .

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Molecular cloning and characterization of a German HIV-1 isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Expression, characterization and purification of simian immunodeficiency virus soluble, oligomerized gp160 from mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

HIV and SIV gp120 binding does not predict coreceptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

HIV Type 1 Variation in World Health Organization-Sponsored Vaccine Evaluation Sites: Genetic Screening, Sequence Analysis, and Preliminary Biological Characterization of Selected Viral Strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

7 January 2021

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

7 January 2021

Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

7 January 2021

Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

7 January 2021

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.08.042

7 January 2021

10.1016/J.VACCINE.2003.08.042

Identifiers

DOI

1 reference

8 December 2017

1 reference